ST
Paid
FEATURED
Standigm BEST
AI platform for de novo drug lead design.
An AI solution that explores latent chemical space to generate novel compounds with desired biological properties, automating molecular structure design to reduce early-stage drug development costs.
PROS
- + Significantly reduces the time for novel compound generation from months to weeks
- + Designs novel small molecule compounds for a requested indication using generative models
- + Integrates predictive models for key drugability properties like ADME/Tox
- + Leverages a comprehensive
- + proprietary chemical database and public/commercial sources
- + Offers a full workflow for hit-to-lead optimization with multi-parameter capabilities
CONS
- - Likely requires custom enterprise contracts or service agreements
- - making it inaccessible to individual researchers.
- - The platform is focused on molecular design and compound generation
- - not comprehensive in-vivo PK/PD prediction
- - Effective use requires high-level expertise in medicinal chemistry and data science for input and model guidance
-
Generating novel small molecule compounds for specific disease indications
-
Performing scaffold hopping to design novel compounds with optimal synthetic accessibility
-
Identifying and optimizing lead compounds that meet multi-parameter criteria (activity
-
ADME/Tox)
-
Accelerating the time-to-lead for drug discovery projects
-
Suggesting new compound structures to secure broad patent protection
